Immunotherapy for SARS-CoV-2: potential opportunities.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

18 citing papers in PubMed, 3 syntheses or guidelines pooled it, 39 citations in OpenAlex.

1. Interferon therapy in patients with SARS, MERS, and COVID-19: A systematic review and meta-analysis of clinical studies.European journal of pharmacology · 2021
   Pooled it
2. A systematic review of pregnant women with COVID-19 and their neonates.Archives of gynecology and obstetrics · 2021
   Pooled it
3. Computational drug discovery and repurposing for the treatment of COVID-19: A systematic review.Bioorganic chemistry · 2021
   Pooled it
4. Clinical Trials of Mesenchymal Stem Cells for the Treatment of COVID 19.Current stem cell research & therapy · 2024
   Review
5. Mental Healthcare in Pediatrics During the COVID-19 Pandemic: A Call for International Public Health Action.Advances in experimental medicine and biology · 2024
   Review
6. Natural killer cells and their exosomes in viral infections and related therapeutic approaches: where are we?Cell communication and signaling : CCS · 2023
   Review
7. Status and Developing Strategies for Neutralizing Monoclonal Antibody Therapy in the Omicron Era of COVID-19.Viruses · 2023
   Review
8. Biomimetic nanoplasmonic sensor for rapid evaluation of neutralizing SARS-CoV-2 monoclonal antibodies as antiviral therapy.Biosensors & bioelectronics · 2023
   Article
9. Natural killer cells in COVID-19: from infection, to vaccination and therapy.Future virology · 2023
   Review
10. Omalizumab may protect allergic patients against COVID-19: A systematic review.The World Allergy Organization journal · 2023
    Review
11. Computed tomography scan in COVID-19: a systematic review and meta-analysis.Polish journal of radiology · 2022
    Review
12. The Immunopathobiology of SARS-CoV-2 Infection.FEMS microbiology reviews · 2021
    Article
13. An outlook on antigen-specific adoptive immunotherapy for viral infections with a focus on COVID-19.Cellular immunology · 2021
    Review
14. Immune checkpoint inhibition in COVID-19: risks and benefits.Expert opinion on biological therapy · 2021
    Article
15. Altered immunoemotional regulatory system in COVID-19: From the origins to opportunities.Journal of neuroimmunology · 2021
    Review
16. Targeting Runt-Related Transcription Factor 1 Prevents Pulmonary Fibrosis and Reduces Expression of Severe Acute Respiratory Syndrome Coronavirus 2 Host Mediators.The American journal of pathology · 2021
    Article
17. Biosensing surfaces and therapeutic biomaterials for the central nervous system in COVID-19.Emergent materials · 2021
    Review
18. Human Coronaviruses SARS-CoV, MERS-CoV, and SARS-CoV-2 in Children.Journal of pediatric nursing
    Review

Corrections and comments

• Comment on
  An Update on Current Therapeutic Drugs Treating COVID-19.2020
• Comment on
  Towards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, and corticosteroids.2020

Authors and funding

2 authors at 2 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as